SCHEMBL3796476

SCHEMBL3796476

CCN(CC)CCNC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c(C)c1C(C)=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.71
KDR P35968 14/20 0.70
PRKAA1 Q13131 10/20 0.70
PRKAA2 P54646 9/20 0.70
PDGFRB P09619 7/20 0.70
FLT3 P36888 4/20 0.70
FGFR1 P11362 4/20 0.70
CSF1R P07333 3/20 0.70
EGFR P00533 3/20 0.70
PLK4 O00444 2/20 0.70
DCLK1 O15075 2/20 0.70
PDPK1 O15530 2/20 0.70
DAPK3 O43293 2/20 0.70
ROCK2 O75116 2/20 0.70
RPS6KA5 O75582 2/20 0.70
RPS6KA4 O75676 2/20 0.70
MAP4K4 O95819 2/20 0.70
CHEK2 O96017 2/20 0.70
NTRK1 P04629 2/20 0.70
INSR P06213 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796480 1.00 AURKA (0.71) AURKAKDRPRKAA1PRKAA2PDGFRB
SCHEMBL3800157 0.83 AURKA (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
SCHEMBL3800161 0.83 AURKA (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
SCHEMBL3802797 0.83 KDR (0.53) AURKAKDRPRKAA1PRKAA2PDGFRB
SCHEMBL3802793 0.83 KDR (0.53) AURKAKDRPRKAA1PRKAA2PDGFRB
Sunitinib SCHEMBL25343938 0.83 KDR (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
Sunitinib SCHEMBL8082 0.83 KDR (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
Sunitinib SCHEMBL20805212 0.83 KDR (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
Sunitinib SCHEMBL30314241 0.83 KDR (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB
Sunitinib SCHEMBL25343935 0.83 KDR (1.00) AURKAKDRPRKAA1PRKAA2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US claimed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US claimed
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US disclosed
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US disclosed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US disclosed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors CDK2, MAP3K19, MAP3K20 AURKA 96/4885KDR 853/4885PRKAA1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.